Bristol-Myers Squibb Company
Marktkapitalisierung
$125.6B
Globaler Rang
#132
Allzeithoch
$139.1B
2026-09-03
Gesamtwachstum
+0%
seit 2026
Market Cap Context
- Larger than 64% of the 367 companies we track (globally).
- Equivalent to 0.4% of United States's GDP (2025 data).
- Just above: #131 Novo Nordisk ($125.9B)
- Just below: #133 Altria Group, Inc. ($124.1B)
- Best year: 1997 (+78%). Worst year: 2002 (-53%).
Bristol-Myers Squibb Company Financial Breakdown (FY 2025)
Source: Yahoo Finance — BMY annual filings (2025) →$48.2B revenue · $13.7B operating income · $7.1B net income
- ●Operating margin: 28.5% on $48.2B in revenue.
- ●R&D is 20.6% of revenue ($10.0B).
- ●Net income margin: 14.6% — $7.1B in profit.
- ●Free cash flow: $12.8B (26.7% of revenue).
Cost / Operating Expenses
Total operating expenses $34.5B
Total
$31.2B
Capital Expenditures
$1.3B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$12.8B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Über Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Verlauf der Marktkapitalisierung von Bristol-Myers Squibb Company (2026–2026)
Bristol-Myers Squibb Company vs Sector Peers by Market Cap
Bristol-Myers Squibb Company vergleichen
Rangverlauf
| Jahr | Marktkapitalisierung | Rang | Veränderung ggü. Vorjahr |
|---|---|---|---|
| 2026 | $125.6B | #132(↑7) | +16.6% |
| 2025 | $107.8B | #139(↓15) | +0.1% |
| 2024 | $107.6B | #124(↓3) | +15.8% |
| 2023 | $92.9B | #121(↓53) | -26.1% |
| 2022 | $125.8B | #68(↑26) | +19.0% |
| 2021 | $105.8B | #94(↓13) | +3.7% |
| 2020 | $102.0B | #81(↓14) | -0.4% |
| 2019 | $102.4B | #67(↓6) | +27.7% |
| 2018 | $80.2B | #61(↓9) | -12.9% |
| 2017 | $92.0B | #52(↓6) | +7.7% |
| 2016 | $85.4B | #46(↓17) | -13.0% |
| 2015 | $98.2B | #29(↑11) | +19.3% |
| 2014 | $82.3B | #40(↑2) | +14.2% |
| 2013 | $72.0B | #42(↑16) | +68.8% |
| 2012 | $42.7B | #58(↓15) | -3.8% |
| 2011 | $44.4B | #43(↑24) | +39.4% |
| 2010 | $31.8B | #67 | +10.1% |
| 2009 | $28.9B | #67(↓14) | +15.0% |
| 2008 | $25.1B | #53(↑28) | -7.3% |
| 2007 | $27.1B | #81(↓13) | +4.8% |
| 2006 | $25.9B | #68(↑4) | +19.9% |
| 2005 | $21.6B | #72(↓11) | -6.1% |
| 2004 | $23.0B | #61(↓15) | -6.3% |
| 2003 | $24.5B | #46(↓3) | +29.4% |
| 2002 | $19.0B | #43(↓18) | -53.0% |
| 2001 | $40.3B | #25(↓4) | -26.2% |
| 2000 | $54.6B | #21(↑4) | +17.1% |
| 1999 | $46.6B | #25(↓8) | -2.8% |
| 1998 | $48.0B | #17(↑2) | +43.6% |
| 1997 | $33.4B | #19(↑9) | +77.5% |
| 1996 | $18.8B | #28(↓2) | +31.2% |
| 1995 | $14.3B | #26(↓1) | +55.2% |
| 1994 | $9.2B | #25 |
Weitere Unternehmen im Sektor Gesundheitswesen
FAQ
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company (BMY) has a market capitalization of $125.6B, making it the #132 largest company in the world by market cap.
What was Bristol-Myers Squibb Company's highest market cap?
Bristol-Myers Squibb Company's all-time high market cap was $139.1B, reached in 2026-09-03. Its highest rank was #68 in 2022.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Bristol-Myers Squibb Company's market cap changed over time?
Bristol-Myers Squibb Company has been tracked since 2026. Its market cap has grown by 0% from $125.6B in 2026 to $125.6B today.